Many PAD patients do not even know they have the disease until it is too late, leading to unnecessary amputations and increasing the risk of other adverse patient outcomes. Awareness is especially limited among Black and Hispanic adults, experts warn, creating an added sense of urgency when looking to accelerate patient education efforts.

Researchers explored data from more than 50,000 TAVR patients who presented with both severe aortic stenosis and stable coronary artery disease, sharing their findings in JACC: Cardiovascular Interventions.

Boston-based Amplitude Vascular Systems is busy investigating the performance of its Pulse IVL platform in a wide variety of patient populations.

Frank J. Hildner, MD, is remembered by colleagues for his significant contributions to the field of interventional cardiology as well as his positivity, warmth and generosity. 

Multiple studies over the years have linked PVL to an increased risk of adverse outcomes. New research out of Italy, however, suggests that device improvements made by Medtronic, Edwards Lifesciences and Boston Scientific may have reduced PVL's influence.

Surgery offers multiple long-term benefits when compared to a more interventional approach, though it is still associated with certain risks of its own. In the end, researchers agree, the decision is one that should involve input from surgeons, cardiologists and others.

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business.